NETBET
30.6.2020 14:29:13 CEST | Business Wire | Press release
None of the top ten car manufacturers are close to meeting EU carbon targets and could face annual fines of €11.4 billion each as a result, new research shows.
The Auto Emissions Report found that Daimler AG is the carmaker that’s furthest away from achieving the 2021 EU target of 95CO2g/km average fleet emissions, while Toyota Industries is the closest to lowering its carbon footprint - but still faces significant fines.
Automakers need to substantially reduce their annual carbon footprint in order to meet EU emissions standards, or else face fines of €95 per CO2g/km that exceeds the target, multiplied by unit sales. Based on the fleet emissions and unit sales of top manufacturers over the last year, this equates to a staggering €11,462,337,802 on average in penalties each.
As well as paying fines for exceeding EU targets, auto manufacturers would also have to offset the emissions of their annual sales. In 2019, top ten car makers would have had to pay a collective €424 billion - or an average of 39.5% of their annual revenue each.
Manufacturers and distance from EU target
Manufacturer |
Distance from EU target - CO2g/km |
Manufacturer |
Distance from EU target - CO2g/km |
Daimler AG |
42 |
Ford Motor Company |
28.7 |
Mazda Motor Corporation |
40.2 |
Hyundai Motor Group |
26.9 |
BMW |
32 |
Groupe PSA |
19.1 |
Fiat Chrysler Automobiles |
29.4 |
Renault |
18.2 |
Volkswagen Group |
29 |
Toyota Industries |
6.3
|
An analysis of the best-selling models of each brand reveals that Group PSA produced the most polluting cars on average last year, which would cost €1.3 billion to offset. Based on EU sales, the most polluting model sold last year was the Renault Clio.
Dissecting the running costs of manufacturers’ flagship models shows that the Mercedes-AMG GT was the most polluting model on the market last year, while the Peugeot 508 was the most environmentally friendly. Despite this, the 508’s carbon footprint is still equivalent to consuming 12,208 litres of gas, or 10,659 litres of diesel.
The transport industry is one of the largest contributors to the global carbon footprint, accounting for an estimated 24% of the world’s greenhouse gas emissions last year. Although many manufacturers are electrifying their fleet to reduce emissions, the car making sector is facing more pressure than ever to tackle their contribution to climate change.
To see the results of the Auto Emissions Report, visit: https://www.netbet.co.uk/auto-emission-report/
Data gathered from a range of sources, including auto manufacturers’ annual reports, EUROPA, transportenvironment.org and Carbon Engineering. Tonnes are metric.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
